Non-Invasive Determination of Fetal Chromosome Abnormalities

Down Syndrome (Trisomy 21) Clinical Trial

Official title: Non-Invasive Determination of Fetal Chromosome Abnormalities

Status Recruiting

Clinical Trial Summary

The overall significance of this study is to develop a laboratory developed test (LDT) to use a new marker in the maternal blood to better identify pregnancies that have a child with a chromosome abnormality such as Down syndrome (trisomy 21), Edward's syndrome (trisomy 18), Patau syndrome (trisomy 13), Klinefelter syndrome, (47, XXY), and other chromosome abnormalities. Accomplishing that task would reduce the need for invasive amniocentesis and CVS procedures.

Clinical Trial Description

n/a

Study Design

Observational Model: Case-Only, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Abnormalities.
• and Other Chromosome
• Chromosome Aberrations
• Chromosome Disorders
• Congenital Abnormalities
• Down Syndrome
• Down Syndrome (Trisomy 21)
• Edward's Syndrome (Trisomy 18)
• Klinefelter Syndrome
• Klinefelter Syndrome (47, XXY)
• Patau Syndrome (Trisomy 13)
• Syndrome

• NCT number: NCT00891852
• Study type: Observational
• Source: Lenetix Medical Screening Laboratory
• Status: Recruiting
• Phase: N/A
• Start date: January 2009
• Completion date: December 2009